The costs of schizophrenia in Spain

被引：2

作者：

Oliva-Moreno J. ^{[1
,6
]}

López-Bastida J. ^{[2
]}

Osuna-Guerrero R. ^{[3
]}

Montejo-González A.L. ^{[4
]}

Duque-González B. ^{[5
]}

机构：

[1] Department of Economics, Universidad Carlos III de Madrid, Fundacion de Estudios de Economia Aplicada (Fedea), Madrid

[2] Canary Islands Health Service, Seminario de Estudios Sociales de la Salud Y Los Medicamentos (Sesam), Universidad Carlos III de Madrid

[3] Universidad Nacional de Educación a Distancia (Uned), Madrid

[4] Faculty of Medicine, Universidad de Salamanca, Salamanca

[5] Seminario de Estudios Sociales de la Salud Y Los Medicamentos (Sesam), Departamento de Economía, Universidad Carlos III de Madrid, Getafe, Madrid

来源：

The European Journal of Health Economics | 2006年 / 7卷 / 3期

关键词：

Cost of illness; Prevalence; Schizophrenia; Spain;

D O I：

10.1007/s10198-006-0350-5

中图分类号：

学科分类号：

摘要：

This study estimated the economic impact of schizophrenia-related direct costs (medical and nonmedical costs) in Spain. Direct medical costs (hospitalizations, outpatient consultations, drug costs) and direct nonmedical costs (costs of informal care) were estimated based on prevalence costs for 2002. The total costs of schizophrenia were estimated at €1,970.8 million; direct medical costs accounted for 53% and informal care costs 47%. Despite having implemented a conservative approach, the health care costs associated with schizophrenia account for 2.7% of total public health care expenditure in Spain. The sum of medical and nonmedical costs give us a better definition of the magnitude of the problem in Spain as well as contributing to helping make the debate on this issue more transparent. © 2006 Springer Medizin Verlag.

引用

页码：182 / 188

页数：6

共 48 条

[1]

Report on Choices in Health Care, (1993)

[2]

Estadísticas de Establecimientos Sanitarios Con Régimen de Internado, (2001)

[3]

Información Terapéutica del Sistema Nacional de Salud, Vol 26, No 2, (2002)

[4]

Información Terapéutica del Sistema Nacional de Salud. Vol 28, No 2, (2002)

[5]

Estudio Depresión Monitor, TNS Healthcare, (2003)

[6]

Baca E., Roca M., Varela C., Prevalence of Comorbidities in Ambulatory Schizophrenic Patients Treated with Antipsychotics, (2004)

[7]

Baca E., Roca M., Varela C., Treatment Profile of Schizophrenic Outpatients in Spain, (2004)

[8]

Van Den Berg B., Brouwer W., Koopmanschap M., Economic valuation of informal care: An overview of methods and applications, Eur J Health Econ, 5, pp. 36-45, (2004)

[9]

Carr V.J., Neil A.L., Halpin S.A., Et al., Costs of schizophrenia and other psychoses in urban Australia: Findings from the Low Prevalence (Psychotic) Disorders Study, Aust N Z J Psychiatry, 37, pp. 31-40, (2003)

[10]

Clark R.E., Xie H., Adarhi-Meija A.M., Sergupta A., Substitution between formal and informal care for persons with severe mental illness and substance use disorders, J Ment Health Policy Econ, 4, pp. 123-132, (2001)

← 1 2 3 4 5 →